← Back
$TEVA All transactions

TEVA PHARMACEUTICAL INDUSTRIES LTD

A

$ Value

$0

Shares

52,173

Price

$0

Filed

Jun 9

Insider

Name

Francis Richard D

Title

President and CEO

CIK

0001673277

Roles

Officer

Transaction Details

Transaction Date

2025-06-05

Code

A

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

52,173

Footnotes

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. | Restricted share units were granted on June 5, 2025, with 13,043 vesting on each of June 5, 2026, June 5, 2027, and June 5, 2028 and 13,044 vesting on June 5, 2029. | The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing Info

Accession No.

0000950170-25-083680

Form Type

4

Issuer CIK

0000818686

Francis Richard D's History

Date Ticker Type Value
2026-03-05 TEVA M
2026-03-05 TEVA $634K
2026-03-05 TEVA M $0
2026-03-04 TEVA M
2026-03-04 TEVA $759K
2026-03-04 TEVA M $0
2026-03-04 TEVA A $0
2026-03-03 TEVA M
2026-03-03 TEVA $1.0M
2026-03-03 TEVA M

Other Insiders at TEVA (90d)

Insider Bought Sold Last
Francis Richard D
President and CEO
$31.1M 2026-03-05
Sabag Mark
See "Remarks"
2026-03-05
Daniell Richard
EVP, Europe Commercial
$7.7M 2026-03-05
Daniell Richard
Exec. VP, European Commercial
2026-01-27
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
$11.6M 2026-03-05
Weiss Amir
Chief Accounting Officer
2026-03-05
Hughes Eric A
See "Remarks"
$3.3M 2026-03-05
Fox Christine
EVP, U.S. Commercial
$546K 2026-03-05
Shields Matthew
EVP, Global Operations
$548K 2026-03-05
Jover Placid
See "Remarks"
$448K 2026-03-05
Lippman Evan
EVP, Business Development
2026-03-04
Savage Brian
Interim Chief Legal Officer
$164K 2026-03-05